CMS Open Payments · Program Year 2024
Corcept Therapeutics
Corcept Therapeutics reported $4,181,168.42 across General Payments, Research, and Ownership to 34,550 physicians and teaching hospitals across 34,877 transactions.
- $4.2M Top quartile payer
- All-tracks total
- 34,877 Top 10% volume
- Transactions
- 34,550 Top 10% reach
- Recipients
- +$1.7M
- General Payments vs PY2023
Corcept Therapeutics reported $4,181,168.42 across all CMS Open Payments tracks (General + Research + Ownership) to 34,550 physicians and teaching hospitals in Program Year 2024 - ranking #300 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,892,659.80, averaging $121.02 per recipient.
How Corcept Therapeutics's $4.2M all-tracks total breaks down
Corcept Therapeutics's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
B
87/100
Total payments
F
49/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer corcept-therapeutics Corcept Therapeutics
$4.2M · #300/1,925 · 0.0% industry · PY2024
- TOT $4.2M
- RANK #300
- SHARE 0.0%
- TXN 34,877
- RCP 34,550
- CAT 8
- GEN $3.9M
- ΔGEN +$1.7M
- TOP1 3.0%
- PY 2024
Volume peers
Nearest volume peer: Johnson & Johnson Surgical Vision, Inc. ($4.2M)
Corcept Therapeutics sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Corcept Therapeutics's CMS-reported General Payments increased by $1.7M (+74.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CORCEPT THERAPEUTICSPY2023: CORCEPT THERAPEUTICSPY2024: Corcept Therapeutics. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,231,107.00
- PY2024
- $3,892,659.80
What the Data Shows for Corcept Therapeutics
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Corcept Therapeutics, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Compensation for Services Other Than Consulting" leads the 8-category general-payment breakdown below at $1.9M (48.4% of General Payments, 784 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Corcept Therapeutics made 8 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $1.9M, 48.4% of General Payments.
Corcept Therapeutics reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (48.4%), Food and Beverage (22.4%), and Travel and Lodging (11.6%). The remaining 5 categories make up 17.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Corcept Therapeutics files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Corcept Therapeutics divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $1.9M | 784 | 48.4% |
| Food and Beverage | $873.1K | 32,077 | 22.4% |
| Travel and Lodging | $451.7K | 1,011 | 11.6% |
| Honoraria | $387.6K | 106 | 10.0% |
| Consulting Fee | $229.4K | 93 | 5.9% |
| Space Rental or Facility Fees | $44.0K | 15 | 1.1% |
| Grant | $15.6K | 3 | 0.4% |
| Education | $7.7K | 461 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $549,145.18 (14.1%) of $3,892,659.80 in this company's General Payments records across 11,467 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Corcept Therapeutics
The five named recipients with the highest reported General Payments from this company
- 1
Hanford Yau
$117,521.35 across 137 reported transactions
- 2
Lance Sloan
$111,218.77 across 93 reported transactions
- 3
Alison Lynn Gracom
$107,362.34 across 149 reported transactions
- 4
Christopher Lucci
$106,988.69 across 99 reported transactions
- 5
Saleemah Fahmi
$106,054.03 across 126 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Corcept Therapeutics ranks #300 of 1,925 by total payments (top 16% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,662 of 1,838 by HHI (bottom 10% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Esperion Therapeutics, Inc. : $1.3M total payments, HHI 121
- Microtransponder, Inc. : $46.1K total payments, HHI 120
- Harmony Biosciences LLC : $1.3M total payments, HHI 120
- Jazz Pharmaceuticals Inc. : $9.9M total payments, HHI 119
- Kairos Surgical Inc : $59.4K total payments, HHI 119
- Antares Pharma, Inc. : $489.5K total payments, HHI 119
- Corcept Therapeutics (this company) : $3.9M total payments, HHI 117
- Orthofix Medical, Inc. : $9.6M total payments, HHI 116
- Exact Sciences Corporation : $3.5M total payments, HHI 115
- BIOTRONIK NRO, Inc. : $814.5K total payments, HHI 114
- New World Medical,inc. : $334.1K total payments, HHI 114
- Sobi, Inc : $3.4M total payments, HHI 114
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Corcept Therapeutics's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Corcept Therapeutics.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Corcept Therapeutics.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ipsen Bioscience Inc.
Sonex Health, Inc.
Responsive Arthroscopy Inc
Sirtex Medical Inc
TransMedics, Inc.
Put this to use
Corcept Therapeutics ranks #300 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Corcept Therapeutics sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Corcept Therapeutics. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.